Our Blog
-
BioUtah Letter on Prioritizing Life Sciences Workers for Vaccine Distribution
December 3, 2020 Mr. Rich Lakin, MSPH, MPA Immunizations Director Utah Department of Health Bureau of Epidemiology PO…
-
ProLung Has a New Name, Gets $3.3 Million Private Placement and More…
ProLung, now IONIQ Sciences (IONIQ), has been on a roll! Last week, the company announced that they had fully…
-
Fluidx Embolic IDE Trial Results Accepted for Late-Breaking Presentation at the SIR Annual Meeting
First podium presentation of IDE Clinical Trial Data of Novel Embolic Device to Treat Cancer
-
Sen. Mike Lee’s Deputy Chief Tours Sorenson Center for Medical Innovation
Senator Lee’s Deputy chief of staff Justin Anthony yesterday toured the new James LeVoy Sorenson Center for Medical…
-
Rarity Bioscience Announces That ARUP Laboratories Has Become the First U.S. Reference Lab To Validate Its Ultrasensitive superRCA Assay
Rarity Bioscience Announces That ARUP Laboratories Has Become the First U.S. Reference Lab To Validate Its Ultrasensitive superRCA…
-
Owlet® Announces Strategic AI Partnership with webAI to Power the Next Generation of Personalized Infant Health and Sleep Insights
Strategic investment in private AI infrastructure positions Owlet to compound value from its growing base of proprietary infant…
-
Nathan Tenney, Aide to Rep. Maloy Tours Utah Life Sciences Companies
Nathan Tenney, Aide to Rep. Maloy Tours Utah Life Sciences Companies
-
Behavioral Health Assessment Using Vocal Biomarkers
Behavioral Health Assessment Using Vocal Biomarkers
-
Wasatch Health Announces Expanded Investment Platform to Accelerate Life Sciences Growth in Utah and the Mountain West
Wasatch Health Announces Expanded Investment Platform to Accelerate Life Sciences Growth in Utah and the Mountain West
-
Owlet’s First Baby Sleep Report Analyzes Data from Over 1.2 Million Owlet Monitored Babies
Report draws on Owlet’s massive infant sleep dataset, one of the world’s largest, to reveal how babies sleep…
-
PhotoPharmics Announces Publication of Phase 2 Clinical Trial Results in Neurotherapeutics and Its Role in the Company’s Phase 3/Pivotal Clinical Trial
Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease